Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | USP2 | O75604 | 1/20 | 0.50 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.50 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.46 |
| ▸ | PDE4A | P27815 | 1/20 | 0.43 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | TOP1 | P11387 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5706423 | 1.00 | LMNA (0.52) | LMNAL3MBTL1TDP1USP2SLCO1B1 | |
| SCHEMBL8586304 | 1.00 | LMNA (0.52) | LMNAL3MBTL1TDP1USP2SLCO1B1 | |
| SCHEMBL420278 | 1.00 | LMNA (0.52) | LMNAL3MBTL1TDP1USP2SLCO1B1 | |
| SCHEMBL17493340 | 1.00 | LMNA (0.52) | LMNAL3MBTL1TDP1USP2SLCO1B1 | |
| SCHEMBL2066243 | 1.00 | LMNA (0.52) | LMNAL3MBTL1TDP1USP2SLCO1B1 | |
| SCHEMBL2228073 | 1.00 | LMNA (0.52) | LMNAL3MBTL1TDP1USP2SLCO1B1 | |
| SCHEMBL1548302 | 1.00 | LMNA (0.52) | LMNAL3MBTL1TDP1USP2SLCO1B1 | |
| SCHEMBL2227363 | 1.00 | LMNA (0.52) | LMNAL3MBTL1TDP1USP2SLCO1B1 | |
| SCHEMBL3116850 | 1.00 | LMNA (0.52) | LMNAL3MBTL1TDP1USP2SLCO1B1 | |
| SCHEMBL28730 | 1.00 | LMNA (0.52) | LMNAL3MBTL1TDP1USP2SLCO1B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021242752-A1 | METHODS OF CONTROLLING ACUTE INFLAMMATORY RESPONSE | ENDOCYTE, INC. (US) | 2021-12-02 | — | — | WO | disclosed |
| US-20210038605-A1 | NOVEL SMALL MOLECULE IMMUNE AGONISTS AND IMMUNE TARGETING COMPOUNDS AND APPLICATION THEREOF | UNIV SHENZHEN (CN) | 2021-02-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210038605-A1 | NOVEL SMALL MOLECULE IMMUNE AGONISTS AND IMMUNE TARGETING COMPOUNDS AND APPLICATION THEREOF | IFNG, IFNAR1, STING1 | LMNA 4873/4885L3MBTL1 3527/4885TDP1 4280/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.